Key result
Electroconvulsive therapy was questioned as the definitive cause of recurrent ventricular tachycardia in a discussed case report due to missing details on stimulus charge, anesthetic agents, and QTc intervals.
Answers are grounded in this paper and cite their sources.
This letter highlights the importance of detailed reporting of ECT parameters and concurrent medications when evaluating rare cardiovascular adverse events like ventricular tachycardia post-ECT.
Sir, Grover and Aggarwal[1] reported a case of an adult female with paranoid schizophrenia, who suffered recurrent ventricular tachycardia (VT) during electroconvulsive therapy (ECT) regimen. We, however, would like to share some concerns regarding the case and the report that emerged from a journal club discussion on the said article. VT in this case was attributed to ECT because (1) the patient in question showed no symptoms or signs of an arrhythmia during the pre-ECT workup or during the detailed cardiology workup after the second ECT and (2) VT manifested only after receiving the electrical stimulus. It therefore becomes vital to know the details of the electrical stimulus (the type of ECT system; sine-wave, brief pulse or ultra-brief pulse; placement of electrodes; and most importantly, the charge delivered in milli-Coulomb during the treatment) as they have affect the electrical conduction system one way or the other.[2] Authors have also not stated whether they changed the anesthetic agent (thiopentone) and muscle relaxant (succinylcholine) to an alternative, that is more cardioneutral after the first ECT. This is important, as rocuronium (muscle-relaxant) and sugammadex (neuromuscular blockade reversal agent) have been used successfully in preventing postictal VT after ECT.[3] We also wondered why lignocaine, that successfully attenuated VT during the second ECT session was not utilised during the third ECT session at all! On a matter that does not directly relate to the issue at hand, authors have not stated whether there was a specific factor that leads to capping the dose of risperidone at 5 mg/day, which is lower than the therapeutic dose for the drug? Authors have also not provided any data on the QTc interval from the two electrocardiograms. That can throw more light on the matter, as patients with VT have shown a higher tendency of having longer QT intervals.[4] Occurrence of major cardiovascular adverse events and/or mortality is rare after ECT.[5] This case requires discussion among mental health professionals, as the presentation is rarer than other cardiovascular mortality, post-ECT. It also differs from other such reports[36789] in many aspects of presentation and management. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Harshe et al. (2020) conducted a letter in Ventricular tachycardia (n=1). Electroconvulsive therapy was evaluated. Electroconvulsive therapy was questioned as the definitive cause of recurrent ventricular tachycardia in a discussed case report due to missing details on stimulus charge, anesthetic agents, and QTc intervals.
Synapse has enriched 10 related papers. Consider them for comparative context: